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1. Introduction  
Numerous physiological functions are regulated by calcium. In fact, ionized intracellular 
calcium (Ca2+) is the most common signal transduction element, a universal cofactor for 
various enzymes and a crucial participant in different physiologically relevant pathways at 
the cell membrane level. Thus, ensuring a stable level of extracellular Ca2+ is a priority for 
preserving many cell functions as automatism of nerve and muscle activity, contraction of 
cardiac, skeletal and smooth muscle, release of neurotransmitters and secretion of endocrine 
and exocrine hormones, among others. 
The levels of extracellular Ca2+ and phosphorus (P) are tightly regulated by complex 
mechanisms that have evolved from a phylogenetic perspective, in order to maintain their 
extracellular concentrations within relatively narrow limits. Among key participants in the 
regulation of Ca2+, parathyroid hormone (PTH), calcitonin and 1-25 dihydroxyvitamin D 
are major hormones involved in mineral ion homeostasis, through their effects on 
parathyroid glands, bone, kidney and intestine. 
Although, injury or removal of the parathyroid glands during neck surgery is by far the 
most common cause of acute and chronic hypoparathyroidism, there are other no so 
common causes as parathyroid hormones or vitamin D related disorders that may 
contribute to an impaired parathyroid function.  
Conventional treatment of chronic hypocalcemia, particularly hypoparathyroidism, is based 
on calcium salts, vitamin D (mainly calcitriol), and drugs that increase renal tubular 
reabsorption of calcium as thiazides. Recently, new treatments have been developed, 
increasing the therapeutic armamentarium for hypocalcemic disorders, as synthetic 
recombinant human parathyroid hormone (rhPTH) 1–34 administered once or twice daily in 
patients with hypoparathyroidism. This treatment modality has proved to reduce urinary 
calcium excretion compared with calcitriol therapy and to maintain serum calcium in the 
normal range, thus avoiding chronic hypercalciuria that may lead to renal function 
impairment, nephrocalcinosis and renal insufficiency in the long term. What is more, new 
rhPTH release formulations are currently under investigation, opening a new field to 
explore for the treatment of hypoparathyroidism.  
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In this chapter, we will discuss the regulation of the metabolism of calcium and phosphorus 
and their integrated pathways to maintain their levels within physiological limits with 
special focus on hypocalcemic disorders and new treatment approaches. 
2. Physiological regulation of calcium and phosphorus metabolism  
Extracellular Ca2+ participates in the regulation of numerous physiological functions, as 
automatism of nerve and muscle activity, contraction of cardiac, skeletal and smooth 
muscle, release of neurotransmitters and secretion of endocrine and exocrine hormones 
among others; thus, physiological concentrations of extracellular ionized Ca2+ remain 
virtually constant at 1.2 mM (5 mg/dL) (Brown, 1991). For these reason, different 
physiological mechanisms are involved for maintaining extracellular Ca2+ level whiting 
these narrow limits that includes parathyroid hormone (PTH), calcitonin and 1-25 
dihydroxyvitamin D as major hormones participating in mineral ion homeostasis, through 
their effects on parathyroid glands, bone, kidney and intestine. 
2.1 General Homeostasis of calcium and phosphorus metabolism 
The bone acts as a true storehouse of Ca2+ and P, containing nearly the total Ca2+ and P of 
the body in its mineral structure. Only 1% of Ca2+ from the bone is in constant exchange 
with extracellular Ca2+ and under tight regulation as this quantitatively minor amounts 
play a crucial physiological role (Kronenberg et al, 2007).  
Extracellular Ca2+ not bound to proteins (albumin and globulins mainly), called as ionized 
Ca2+, acts as the biological active fraction. Its physiological concentration remains virtually 
constant at 1.2 mM tightly controlled by hormonal mechanisms.  
In contrast, resting cytosollic calcium concentration is about 100 nM but fluctuations allow 
increases up to 1 microM (100 folders) through cellular activation by releasing Ca2+ from 
intracellular stores (endoplasmic reticulum, mitochondria) and through activated channels 
thanks to a very large chemical gradient (10,000:1). Intracellular Ca2+ acts as a key 
intracellular messenger and cofactor for various enzymes and biological functions (Valero et 
al, 2008). 
On the other hand, organic P is a main constituent and coenzyme for numerous 
physiological processes as replication, differentiation, development, energy expenditure and 
storage. Any alteration on P homeostasis cause severe disorders that affect global organ 
functions (Figure 1). 
 
 
 
Fig. 1. Calcium concentration in the cell, plasma and intracellular stores and main fluxes 
(endoplasmic reticulum). 
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The levels of extracellular Ca2+ and P are tightly regulated by complex mechanisms in a 
coordinated way that has evolved from a phylogenetic perspective in order to maintain their 
extracellular concentrations within relatively narrow limits.  
2.2 Parathyroid hormone 
The parathyroid cell is a prototypical extracellular Ca2+ sensing cell (Brown, 1998).  This 
characteristic allows the constant monitoring of extracellular ionized Ca2+ levels, thus, 
increasing extracellular Ca2+ is sensed by plasma membrane receptor of parathyroid glands 
cells (the calcium sensing receptor –CaSR-) that mediates the reduction of PTH hormone 
secretion (Figure 2) (Riccardi & Gamba, 1999).  
 
 
Fig. 2. PTH regulation on parathyroid gland by extracellular Ca2+ levels through CaSR 
http://chemistry.gravitywaves.com/CHE452/20_Calcium%20Homeostasis16.htm March 
15 2011. Dr Noel Sturm 
In last years, inherited diseases caused by mutations of the CaSR have been studied (Health 
et al, 1996). Loss-of-function mutations induce a loose of sensitivity to extracellular Ca2+ 
levels and a disruption of the downregulation mechanism of PTH secretion as in familiar 
hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. These inherited 
diseases are characterized by mild or severe hypercalcemia. Gain of function mutations have 
been described in recent years, and in these conditions the hypersensitivity to Ca2+ levels 
cause hypocalcemia due to a premature inhibition of PTH secretion by the parathyroid 
gland as in autosomal dominant hypoparathyroidism (Polak et al, 1994).  
Parathyroid hormone (PTH) is secreted by parathyroid glands regulated by ionized 
extracellular Ca2+ through CaSR. PTH is a 84 amino acids peptide hormone synthesized as 
a large pre-prohormone that exerts its biological effects on its intact configuration or by 
different amino terminal fragments. A continuous PTH high level as seen in 
hyperparathyroidism induces stimulation of bone resorption and the release of Ca2+ and P 
to plasma, and consequently leads to a decrease of bone mineral density. On the other hand, 
intermittent administration of PTH has the opposite effect and it is the basis of its use in the 
treatment of severe osteoporosis. In the kidney, PTH acts stimulating Ca2+ reabsorption and 
P urinary excretion. Indirectly, PTH provides active vitamin D by hydroxylation of 
25(OH)D3 in  position 1 (1,25(OH)2D3) which increases calcium absorption at the gut level. 
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In summary, PTH acts as a Ca2+ rising hormone and a major regulatory of Ca2+ 
metabolism; conversely, increasing levels of Ca2+ exert a downregulation feed back effect 
on PTH secretion (Shoback, 2008).   
2.3 Calcitonin 
Calcitonin is a 32 amino acid peptide hormone secreted by parafollicular cells (C cells) of the 
thyroid gland. Despite of its important role in few vertebrae animals, in humans its role on 
Ca2+ and P metabolism is less important. However, it is used in the treatment of 
hypercalcemia due to its decreasing Ca2+ renal reabsorption effect and its inhibition Ca2+ 
bone resorption; thus, calcitonin has a net hypocalcemic effect on plasma Ca2+ levels in 
hypercalcemic disorders. Its regulation is mediated by Ca2+ ionized extracellular levels in 
part through the CaSR as in parathyroid glands, although other hormone and vitamin 
factors could also play an important role. Finally, calcitonin is also secreted by different 
neuroendocrine tumours, as medullary thyroid carcinoma, and it used as tumour marker 
(Kudo et al, 2011).   
2.4 Vitamin D 
Vitamin D acts as a real hormone. Its synthesis and tissue concentration is more dependent 
of seasonal and sun exposure factors rather than oral intake. Endogenous inactive vitamin D 
(colecalciferol-Vitamin D3) is synthesized by ultraviolet radiation, although nutritional 
alternative sources (supplemented dairy products, fat fish and liver) could eventually 
provide sufficient quantities for covering daily needs. Vitamin D3 activation requires 
hydroxylation of the 25th and 1st positions to get full biological activity (1,25(OH)2D3); this 
process takes place in the liver and kidney where hydroxylation is successively performed 
and at the kidney level activation of 1-hydroxilase is partially dependent of PTH. Vitamin D 
can also be hydroxilated at position 24 which renders inactive the molecule.  
The main effect of vitamin D on Ca2+ and P metabolism is to stimulate calcium absorption 
in the bowel by means of the binding of its active form 1,25(OH)2D3 to the vitamin D 
nuclear receptor (VDR) (Shiohara et al, 2005). A less pronounced but also an important effect 
of vitamin D is to promote Ca2+ and P apposition in the  bone and to stimulate calcium 
excretion in the kidney. The VDR is a ubiquitous receptor which is expressed in most tissues 
and cell lines and in fact vitamin D has been implicated in numerous biological actions as 
activation of the immune system, autoimmune diseases, cardiovascular risk, proliferation 
and differentiation of cancer cell lines among others (Fernandez et al, 2009; Mathieu & 
Adorini, 2002;  Nagpal et al, 2005). 
Calcium and vitamin D intake is currently though to be under normal requirements, 
especially in old populations due to loss of efficiency of vitamin D synthesis and age-related 
down regulation of 1alpha kidney hydroxylation in relation with kidney function, as well as 
insufficient sun exposure in aged people. At the moment, a worldwide high prevalence of 
vitamin D deficiency has been described (Rosen, 2011).    
2.5 Integrated homeostasis of calcium metabolism 
The levels of extracellular Ca2+ and P are tightly regulated by complex interrelation of PTH, 
calcitonin and 1-25 dihydroxyvitamin D through their balanced effects on parathyroid 
glands, bone, kidney and intestine target organs (Figure 3). 
PTH secretion is regulated by extracellular Ca2+ levels and activation of 25(OH)D3 to 
1,25(OH)2D3 is regulated by PTH action on kidney. 1,25(OH)2D3 enhances calcium 
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absorption on gut. On the same way, calcitonin regulation is mediated by Ca2+ ionized 
extracellular level. These complex mechanisms work in concert to keep Ca2+ and P+ in a 
constant concentration for maintaining under optimal conditions some critical  physiological 
functions as automatism of nerve and muscle activity, contraction of cardiac, skeletal and 
smooth muscle, release of neurotransmitters and secretion of endocrine and exocrine 
hormones among others.  
 
 
Fig. 3. Integrated physiological homeostasis of calcium metabolism.  
Calcium and vitamin D insufficiency leads to an increase in calcium intestinal absorption, 
renal uptake and calcium bone reabsorption. The first step to reach the new equilibrium is 
initiated by the low extracellular calcium concentration which is sensed by CaSR and 
triggers PTH secretion by the parathyroid glands. The increment of PTH level increases the 
synthesis of the activated form of vitamin D and stimulates absorption of tubular calcium on 
kidney. On the other hand, 1,25 OH vitamin D acts on the nuclear pathways of the 
entherocytes to increase absorption of dietary calcium, which is quantitatively the most 
important response to calcium and vitamin D insufficiency. To summarize, chronic calcium 
and vitamin D insufficiency provoques a continuous compensatory hyperparathyroidism 
aimed to maintain Ca2+ and P+ into the physiological levels; this chronic hyperactivation of 
the parathyroid glands may have deleterious consequences at the long term. 
3. Hypocalcemic disorders  
Any alteration of this close balance between the hormones involved in calcium metabolism 
could originate disorders characterized by the presence hypocalcemia.  
Although, injury or removal of the parathyroid glands during neck surgery is the most 
common cause of acute and chronic hypoparathyroidism, other not so common causes 
should be evaluated and ruled out, mainly caused by alteration in intestinal absorption 
(vitamin D related) or by decrease reabsorption at the bone and kidney levels (parathyroid 
hormones related). 
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3.1 Parathyroid hormones related disorders 
Parathyroid hormones related hypocalcaemia could be differentiated from other causes by a 
low or inappropriately normal PTH level in the presence of low calcium levels, mild 
hyperphosphatemia and low 1,25(OH)2D3.  
PTH related causes of hypocalcemia include: 
3.1.1 Parathyroid glands destruction  
Injury or removal of the parathyroid glands during neck surgery is the most common cause 
of acute and chronic hypoparathyroidism. Its incidence rate is usually related to surgeon’s 
experience, the type of pathology and the surgical technique performed (Sthepen, 2000). 
Although postsurgical hypoparathyroidism is usually a transitory problem, occasionally, it 
persists in 0.4%-33% of cases depending on the series (Page & Strunsky 2007; Torregrosa et 
al, 2005). It may be caused by vascular interruption or involuntary removal during surgery 
and it uses to be permanent if there is no remission after 6-9 months after surgery.  
After hyperparathyroidism adenoma removal, a transient suppressive hypoparathyroidism 
can occur in the first 48 hours after surgery of functional nature. In these cases, hungry bone 
syndrome should be ruled out and could be identified as hypophosphatemia is virtually 
always an associated feature after surgery of a severe and of long duration 
hyperpathyroidism.   
However, any infiltrative or autoimmune disease that affects all parathyroid glands could 
cause hypoparathyroidism. Wilson disease, hemochromatosis, metastic disease can infiltrate 
parathyroid glands causing their dysfunction (Angelopoulos et al, 2006). Autosomal 
recessive autoimmunity hypoparathyroidism can be part of autoimmunity polyglandular 
syndrome type 1, in which Addison disease and mucocutaneous candidiasis are found 
together with hypocalcemia (Husebye et al, 2009). This syndrome has been related to the 
autoimmunity regulatory gene AIRE. Autoimmunity antibodies against parathyroid glands 
and CaSR can support this diagnosis (Dittmar & Kahaly, 2003).  
3.1.2 Congenital/inherited parathyroid disorders  
Transient neonatal hypocalcaemia is a quite frequent disorder that is usually resolved 
during the first days after birth. Hyperparathyroidism and diabetes of the mother are the 
most common causes. However, hypocalcemia disorders that are not resolved during first 4 
weeks or life require a more extended diagnosis work-up. Inactivating mutations of some 
transcription factors as glial cell missing factor (GCM) and SOX3 have been related to 
neonatal hypoparathyroidism.  
In some cases, hypoparathyroidism is part of more complex malformative syndromes 
arising during the embryonic development, as Di George’s syndrome. Di George’s 
syndrome or velo-cardio-facial syndrome is the most frequent severe malformation (1/3000) 
and it is caused by embryonic disorder of third, fourth and fifth branchial pouches, resulting 
in the absence of parathyroid glands associated with cardiac malformations, abnormal 
facies, thymus hypoplasia, and cleft palate. It is caused by deletions in 22q11, and less 
frequently in 10p (Kobrynski & Sullivan, 2007). Other not so common causes of 
neonatal/inherited hypoparathyroidism are Kenny-Caffey syndrome and Barakat 
syndrome among others.   
Gain of function mutations of CaSR amino-terminal domain have been published in recent 
years; in these cases, hypersensitive sensing to Ca2+ levels cause hypocalcemia by 
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premature inhibition of PTH secretion by the parathyroid glands expressed as an autosomal 
dominant hypoparathyroidism (Pollak et al, 1994). In these patients hypocalcemia is found 
together with hypercalciuria and normal PTH. In such a situation, treatment with vitamin D 
results in the development of hypercalcemia which may lead to nephrocalcinosis and renal 
failure; thus, treatment is aimed to avoid symptoms of hypocalcemia and not to achieve 
normocalcemia (Pearce et al, 1996).  
3.1.3 Pseudohypoparathyroidism   
Pseudohypoparathyroidism is characterized by peripheral PTH resistance despite of elevated 
PTH levels, and hypocalcaemia plus hiperphophatemia plasma levels similar to what is found 
in hypoparathyroidism after having ruled out magnesium deficiency and renal failure. It may 
be associated to a characteristic morphotype called Albright´s hereditary osteodysthophy. Its 
genetic bases and clinical features will be described in detail in another chapter.  
3.2 Vitamin D related hypocalcemia 
Hypocalcemia syndrome due to vitamin D related disorders is mainly caused by alterations 
in intestinal absorption of dietary calcium. Hypocalcemic disorders in the context of vitamin 
D deficiency are characterized by elevated PTH plasma levels and hypophosphatemia with 
an  increased renal phosphate clearance (Figure 4). Increased PTH is of compensatory nature 
aimed to maintain Ca2+ and P+ within the physiological levels by calcium mobilization 
from skeleton, increased renal reabsorption of calcium and increased renal 1alpha 
hydroxylation.  
 
 
Fig. 4. Adaptation to vitamin D and calcium insufficiency (adaptation pathways on bold 
type). 
Vitamin D related hypocalcaemia could be caused by: 
3.2.1 Vitamin D absorption/synthesis deficiency  
Vitamin D deficiency is mostly seen in old people, although younger populations may also 
suffer from this condition. As vitamin D could be sourced by skin synthesis under 
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ultraviolet irradiation and/or dietary intake, any deficiency on dietary intake or reduction 
on intestinal fat-soluble vitamin D absorption (gastrectomy, intestinal illness, chronic 
hepatic insufficiency) and any decrease in skin synthesis due to insufficient solar irradiation 
or used of high solar protective factor sun blocks, could cause a vitamin D deficiency. It also 
causes a compensatory hyperparathyroidism and has been correlated with seasonal 
psychiatric and immune disorders in northern countries (Rosen, 2011).  
Modern food industry has supplemented dairy products with vitamin D although it has not 
been correlated with improvements in general population vitamin D levels. 
3.2.2 Impaired 1 or 25 alpha hydroxilation of Vitamin D   
Any alteration on hepatic or kidney functions could lead on deficient hydroxylation of 
vitamin D, as in renal or liver failure. This would cause an intestinal calcium absorption and 
a compensatory increase in circulating PTH.  
It is a common clinical entity especially in chronic renal failure under dialysis. The failure of 
1alpha hydroxilation at the kidney level causes a decrease in plasma calcium by 
malabsorption of dietary calcium intake and a compensatory elevation of PTH (secondary 
hyperparathyroidism) without an increased phosphate clearance because of kidney failure. 
Treatment of compensatory hyperparathyroidism is based on the administration of the 
active form of vitamin D (1-25(OH)2 Vit D) to cover 1alpha hydroxilase deficit,  an increase 
in calcium intake and phosphate binders (Messa et al, 2010). Regulation of PTH secretion 
with non hypercalcemic Vitamin D analogs and calcimimetics (parathyroid CaSR 
sensitizers) has been a revolution in the treatment of secondary hyperparathyroidism 
associated to renal failure (Borstand et al, 2010).  
3.2.3 Impaired entero-hepatic circulation of vitamin D  
Vitamin D is a fat-soluble vitamin, so it is under entero-hepatic circulation and adiposity and 
hepatic deposit. Any alteration on entero-hepatic circulation or accelerated hepatic metabolism 
and its nature is mainly drug-induced: anticonvulsants, tuberculostatic treatment, and bile 
acid sequestrants; any of these could cause an accelerated loss of vitamin D.  
3.2.4 Calcitriol resistance-Hereditary vitamin D resistant rickets 
Some inherited disorders have been described to be associated with vitamin D resistance; 
their frequency is very low. They are characterized by a biochemical profile concordant with 
vitamin D deficiency and compensatory hyperparathyroidism with normal or even elevated 
levels of vitamin D that indicates a resistance vitamin D status. Most mutations described in 
vitamin D resistant rickets involve intranuclear vitamin D receptor (VDR) at the DNA 
binding domain and it affects the regulation of gene expression (Mallory et al, 2004).  
Clinical features are variable but it uses to appear during childhood with hypocalcaemia 
and hypophosphatemia, associated with alopecia, bone deformations and short stature.  
Treatment with high doses of calcitriol do not use to be successful, although it depends on 
the specific mutations on VDR. Vitamin D analogues have opened new therapeutic 
possibilities on this rare illness.  Treatment with sequestrant compounds could cause an 
accelerated loss of vitamin D.  
3.3 Other causes 
Other hypocalcaemia causes include: bone apposition in osteoblastic metastasis; sequestration 
by intravascular drugs or by acute hyperphosphatemic states (rhabdomyolysis, 
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chemotherapy); treatment or ion alterations and vitamin D insufficiency in HIV infected 
patients; critical illness as acute pancreatitis. 
4. Acute hypocalcaemia treatment  
Acute hypocalcaemia is a medical emergency that requires a quick diagnosis and treatment. 
However, chronic hypocalcaemia is frequently asymptomatic and treatment must be aiming 
to normalization of calcium levels without increasing complications (Cooper & Gottoes, 
2008).  
Acute hypocalcaemia can be diagnosed by measuring total calcium levels using protein 
correction to calculate free extracellular calcium (a decrease in calcium of 0.8 mg/dl for 
every 1 g/dL decrease in albumin) or by direct monitoring of ionized Ca2+ (Kronenberg et 
al, 2007). 
Symptoms are correlated with acute instauration and magnitude of the deficiency, 
especially in relation to neuromuscular excitability as carpopedal spasm. In acute and severe 
cases of hypocalcemia general tetany, broncospasm and serious cardiac arrhythmias have 
been described, thus serum calcium levels must be measured frequently in this period, and 
electrocardiographic monitoring must be done during initial replacement therapy. 
Acute hypocalcemia treatment requires prompt normalisation of calcium plasma levels 
using intravenous calcium infusion; other ions alterations are particularly important, i.e. the 
correction of hypomagnesaemia that causes impaired secretion of PTH from parathyroid 
glands and precludes the correction of hypocalcemia. 
5. Chronic hypocalcemia treatment  
The conventional treatment of chronic hypocalcemia and hypoparathyroidism is based on 
calcium salts, vitamin D (mainly calcitriol), and drugs that increase renal tubular 
reabsorption of calcium as thiazides. However, over the past few years, the administration 
of synthetic recombinant human parathyroid hormone (rhPTH) 1–34 once or twice daily, 
even with more physiological releasing devices in patients with hypoparathyroidism has 
proved to reduce urinary calcium excretion compared with calcitriol therapy, and to 
maintain serum calcium in the normal range, thus avoiding chronic hypercalciuria that may 
lead to renal function impairment, nephrocalcinosis and renal insufficiency in the long term. 
On the other hand, new vitamin D analogues have been investigated to maintain calcium 
levels on normal range without hypercalciuria complications. 
In this section we will describe conventional and new treatment approaches of chronic 
hypocalcemia mainly focused on post surgical hypoparathyroidism, due to the important 
innovations appeared in last years.  
5.1 Conventional treatments  
The conventional treatment of chronic hypocalcaemia and hypoparathyroidism is based on 
calcium salts, vitamin D (mainly calcitriol), and drugs that increase renal tubular 
reabsorption of calcium as thiazides.  
Treatment objectives are to maintain free ionized calcium levels within the normal interval 
or plasma calcium in the lower half or slightly below the normal range (8.0-8.5 mg/dL), and 
to avoid hypercalciuria (< 250 mg urine calcium/24 hours) and other treatment 
complications. It should be directed at the underlying disorder (Shoback, 2008).  
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5.2 Calcium salts 
Long-term treatment of patients with chronic hypocalcemia is warranty with 1 to 3 g of 
elementary calcium per day in the various forms of salts available (table 1) because of the 
increased excretion of calcium. Interrupting the supplement can rapidly lower an elevated 
calcium value. It should be must be scheduled in 3-4 doses with meals to facilitates its 
absorption. Calcium carbonate is by far the most used calcium salts due to its low cost, 
despite of gastrointestinal adverse effects and that it requires gastric acidification to assure 
its absorption; thus achlorhydric patients or under proton-pump inhibitors treatment should 
be avoid unlike citrate calcium and should be taken with food or citrus drinks to promote 
maximal absortion. Besides, calcium citrate is preferable because it increases urinary citrate 
thus helping calcium to stay in solution (Harvey et al, 1988). Of the calcium preparations 
available, only the carbonate and citrate salts contain sufficient elemental calcium (per 
tablet) for the efficient treatment of most patients with hypoparathyroidism. Other 
preparations may be used in patients who cannot tolerate citrate and carbonate salts. The 
percentage of elemental calcium is lower in these other preparations, and do not adds any 
benefit (Maeda et al, 2006; Shoback, 2008). 
 
Calcium Salts Ca element content 
Milligrams of salt needed 1 g 
preparation 
elementary calcium 
Calcium Carbonate 40% 2500 
Calcium Phospathe 38% 2631 
Calcium Chloride 27% 3700 
Calcium Citrate 21% 4762 
Calcium Lactate 13% 7700 
Calcium Gluconate 9% 11100 
Table 1. Calcium salts available. Calcium carbonate: constipation is a common side effect; 
calcium carbonate is best absorbed with meals and with acid present in the stomach.  
Calcium citrated: Recommended in patients who have achlorhydria or who are taking a 
proton-pump inhibitor, in order to achieve sufficient absorption of calcium (Maeda et al, 
2006). 
5.3 Vitamin D 
All patients with hypoparathyroidism must be treated with vitamin D or analogues in 
addition to calcium. Vitamin D chosen must be selected depending on the underlying 
disorder, thus impaired renal 1alpha hydroxylation should be treated with 1alpha 
hydroxilated analogues, but vitamin D insufficiency could be treated with non hydroxilated 
vitamin D metabolites (Cooper & Gittoes, 2008).  
Compared to PTH, replacement with calciferol steroids leads to a higher urinary excretion 
of Ca with an increased risk of nephrocalcinosis. Vitamin D toxicity is an important concern 
and may occur at any time. Manifestations may include altered mental status, fatigue, thirst, 
dehydration, reduced renal function, nephrolithiasis, and constipation. Treatment involves 
discontinuation of the vitamin D preparation and the calcium salt intake. Depending on the 
severity, and especially if the toxic effects are related to treatment with vitamin D 
metabolites with long half-lives, intravenous saline infusion and possibly oral 
glucocorticoids may quickly antagonize vitamin D action and restore normocalcemia in a 
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short period of time. Levels of 25-hydroxyvitamin D must be monitored, even in patients 
receiving calcitrol and alfacalcidiol to assess vitamin D dosage adequacy. The target 25-
hydroxyvitamin D level is 30 ng/ml.  
The current most used drugs are dihydrotachysterol (average half-time 7 days), 
alphacalcidol (average half life-2 days) and calcitriol (average half life-1 day) depending on 
underlying pathology (table 2). Not all drugs are available in all countries and short half-life 
compound are more recommendable due to its higher security. Theorically, for patients 
with labile calcemia, dihydrotachysterol may be preferable because it provides better 
stability but a higher risk of intoxication. When an additional rapid effect is needed or 
security is the priority short-acting drugs can be added. (Maeda et al, 2006). 
On hypoparathyroidism, calcitriol is preferred over vitamin D2/D3 because of its potency, 
rapid onset and offset of action. The vast majority of patients require calcitriol in dosages of 
0.25 µg, taken twice daily, and extremely rare cases up to 0.5 µg four times daily. However, 
vitamin D and calcium dosage show a remarkable variability so straight monitoring and 
titration is warranted  at the beginning of the treatment. 
 
Vitamin D 
metabolites 
25 / 1a 
hydroxilation 
required 
Dosage per day 
Onset of 
action 
Offset of 
action 
Vitamin D2 
(ergocalciferol)/ 
Vitamin D3 
(cholecalciferol) 
+/+ 
25,000-100,000 
UI once daily 
10-14 days 14-25 days 
1, 25 OH Vitamin D 
(Calcitriol) 
-/- 
0.25-1 ug twice 
daily 
1-2 days 2-3 days 
1a hydroxivitamin D 
(alfacalcidiol) 
+/- 0.5-3.0 ug daily 1-2 days 5-7 days 
Dihydrotachysterol -/- 
0.2-1.0 mg once 
daily 
4-7 days 7-21 days 
25 (OH) vitamin D 
(Calcidiol) 
-/+ 0.625-5 mg 4-8 weeks 6-12 weeks 
Table 2: Vitamin D metabolites and actions (Maeda et al, 2006; Shoback, 2008). 
5.4 Enhanced calcium renal tubular reabsorption: Thiazides 
Hypoparathyroidism causes increased excretion of urinary calcium in relation to serum 
calcium and chronic vitamin D treatment predisposes to hypercalciuria, nephrolithiasis, and 
nephrocalcinosis. The use of drugs that increase renal tubular reabsorption of calcium as 
thiazides could be useful in hypocalcemia as complementary treatment and may help to 
control hypercalciuria (Porter et al, 1978). In fact, patients should be evaluated annually to 
rule out complications of vitamin D chronic treatment as nephrocalcinosis by imaging 
techniques and cataracts with an ophthalmic revision (Levine , 2001), besides high water 
intake is recommended, at least 1.5–2.5 L/day.   
5.5 New treatment approaches  
Treatment of hypoparathyroidism/hypocalcemia with vitamin D metabolites and calcium 
salts are usually well tolerated. However, quality of life studies suggest that despite 
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optimization or normalization of biochemical values, patients with treated  
hypoparathyroidism  show scores of depression, anxiety and somatisation higher than 
matched controls (Arlt et al, 2002). What is more, vitamin D and calcium salts are not an 
absolutely safe treatment. In fact, treatment is aimed to target low-normal calcium levels in 
order to prevent hypercalciuria and deterioration of renal function at long term.  
In last years, the administration of synthetic human PTH 1-34 once or twice-daily in patients 
having hypoparathyroidism has proved to reduce the level of urinary calcium excretion 
compared with calcitriol therapy as well as maintaining serum calcium in the normal range, 
avoiding chronic hypercalciuria that may lead to impairment of renal function, 
nephrocalcinosis and renal insufficiency. Cost and inconvenience of injection treatment in 
the case of rPTH are the reasons why currently classic treatment with vitamin D plus 
calcium is preferred, despite the risk of hypercalciuria and long term impairment of renal  
function. However, in recent years, successful rhPTH treatment has been reported in cases 
of hypocalcemia and hypoparathyroidism not controlled by conventional therapy, thus 
indicating its usefulness is such a resistant cases (Angelopolulos et al, 2007; Mahajan et al, 
2009; Puig-Domingo et al, 2008, Sanda et al, 2008, Shiohara et al, 2006; Winer et al, 2008). 
On the other hand, research on calcium sensing receptor and vitamin D analogues have 
opened new and promising investigation in future treatments. In fact, in last years clinical 
availability of cinacalcet, the agonist of Calcium Sensing Receptor has proved to be effective 
for the treatment of hyperparathyroidism (Marcocci et al, 2009). Research on antagonists of 
calcium sensing receptor (calcilytic agents) may be used to promote inactivation of the 
receptor in the parathyroid glands and increase PTH secretion, specially in those 
hypocalcemic patients with activated CaSR mutations (Nemeth et al, 2001; Leth et al, 2010). 
5.6 Recombinant human PTH 
Hypoparathyroidism is one of the few endocrine diseases for which hormone-replacement 
therapy is not the treatment approach. Over the last 10 years, some clinical assays using 
synthetic recombinant human parathyroid hormone 1–34 (rhPTH) administered once or 
twice daily in adults and children with hypoparathyroidism, have proved to maintain 
serum calcium in the normal range as well as reducing urinary calcium excretion compared 
with conventional treatment with vitamin D (Winer et al, 1993, 1996, 1998, 2003, 2008, 2010). 
This treatment modality may prevent renal function impairment, nephrocalcinosis and renal 
insufficiency in the long term as it avoids the chronic hypercalciuric state associated to 
vitamin D administration. On the other hand, many studies have shown that rhPTH 
treatment in adult subjects with osteoporosis produces a rapid rise in bone mineralization, 
which may contribute to a faster recovery of lost bone mineral content of these patients 
(Farocki et al, 2007).  
Despite these advantages, rhPTH has not become the treatment of choice for 
hypoparathyroidism, because conventional treatment with vitamin D and calcium salts is 
usually well tolerated, and rhPTH injection is more expensive. However, in recent years, 
successful rhPTH treatment has been reported in cases of hypocalcaemia and 
hypoparathyroidism not controlled by conventional therapy as an off-label treatment. 
Only a few small, randomized trials have assessed the use of injectable PTH (1-34) and 
supplemental calcium in patients with this condition in a relative short period of follow-up 
of 3 years. In those trials, rhPTH has proved to maintain calcium levels between normal or 
slightly below normal range but with a significantly reduction of urinary calcium excretion. 
Twice-daily rhPTH versus once allowed a marked reduction in the total daily PTH 1–34 
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dose, with less fluctuations in serum calcium, normalization of urine calcium and 
significantly improved metabolic control both in adults and children. Also, rhPTH efficacy 
has been extensively published in case reports dealing with hypocalcemic disorders not 
controlled under conventional treatment, some of them trying to mimic more physiological 
delivery as using multipulse subcutaneous pump PTH delivery (Puig-Domingo et al, 2008). 
Major concerns of rhPTH use are related to safety; those data have been obtained mainly 
from osteoporosis treatment studies. Animal toxicity studies have raised concerns regarding 
dose-dependent PTH effects on the bone (Sato et al, 2002). Long-term, supraphysiological 
doses of recombinant human PTH 1–34 (rhPTH), given under continuous delivery rather 
than in a pulsatile way to rats with normal functioning parathyroid glands, was associated 
to an increased risc of osteosarcoma development. However, this higher risk has been 
associated to a particular effect on rat bones and does not seem relevant to PTH-deficient 
patients receiving physiological replacement doses. In fact, post commercialisation follow-
up has not detected an increase in human osteosarcoma diagnosis until now (Harper et al, 
2007). Anyway, more physiological release of PTH as using subcutaneous pumps delivery 
or patch could be even a safer alternative (Horwitz & Stewart, 2008).  
5.7 Calcium sensing receptor antagonists  
PTH secretion is regulated by a cell surface receptor that detects small changes in the level of 
plasma calcium, the calcium sensing receptor (figure 2). This receptor provides a 
particularly interesting and new molecular target for drugs useful for treating calcium and 
bone disorders. At the moment, a calcimimetic (compounds that mimic or potentiate the 
effects of extracellular calcium at the CaSR) is commercialized as cinacalcet (Mimpara ®) 
and it is approved and used in non surgical or tertiary hyperparathyroidism (Marcocci et al, 
2009).  
In the same way, molecules that blocked CaSR activity will stimulate PTH secretion. 
Although, there is no calcilytic compound available yet for therapeutic human use, some of 
them are under research with promising preliminary results, especially for the treatment of 
patients with CaSR activating mutations whose treatment with vitamin D and calcium does 
not correct the underlying pathophysiological defect, and they often worsen hypercalciuria 
and accelerate kidney stone formation or nephrocalcinosis resulting in impaired renal 
function under conventional treatment (Letz et al, 2010).  
6. Conclusion  
Numerous physiological functions are regulated by calcium metabolism, thus, ensuring a 
stable level of extracellular Ca2+ is a priority for preserving normal homeostasis. In this 
respect, levels of extracellular Ca2+ and phosphorus are tightly regulated by complex 
mechanisms in which key participants are parathyroid hormone, calcitonin and 1-25 
dihydroxyvitamin D through their effects over parathyroid glands, bone, kidney and 
intestine. Any alteration of this close balance between the hormones involved in calcium 
metabolism could originate hypocalcemia.  
Although post surgical hypoparathyroidism is the most common cause, diagnosis and 
treatment of hypocalcemic disorders require a detailed study and infrequent causes should 
also be evaluated and ruled out. Hypoparathyroidism could be classified into two main 
groups: vitamin D related causes and parathyroid hormone related causes. Although, 
conventional treatment of chronic hypocalcaemia and hypoparathyroidism is based on 
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calcium salts, vitamin D (mainly calcitriol) and drugs that enhance renal tubular 
reabsorption of calcium, the administration of synthetic recombinant human parathyroid 
hormone (rhPTH) 1–34 and research in calcium sensing receptor have opened new 
promising fields in the last few years.   
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